Division of Oncternal Therapeutics Inc.
Latest From GTx Inc.
In a review of biopharma start-up dealmaking and financing activity from January through March, based on data from Strategic Transactions, Anthos completed the largest venture capital round in the first quarter, raising $250m.
All-stock transaction combines privately held Oncternal with GTx, which had been considering its strategic alternatives. Biogen acquires gene therapy biotech Nightstar, MaxCyte and Kite expand their CAR-T partnership.
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Therapeutic Areas
- Gynecological, Urological
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Oncternal Therapeutics Inc.
- Senior Management
Marc S Hanover, CEO
Diane C Young, MD, VP, CMO
- Contact Info
Phone: (901) 271-8622
175 Toyota Plaza
Memphis, TN 38103
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.